Impax loratadine approval
This article was originally published in The Tan Sheet
Executive Summary
Generics firm to begin shipments of loratadine 5 mg/pseudoephedrine 120 mg tablets to Schering-Plough, Wyeth "within days" of FDA's Jan. 30 approval of firm's ANDA (76-050). Impax Labs notes it has been manufacturing Claritin-D 12-Hour equivalent since November. Firm says it received "first-to-file" status with 180 days of generic marketing exclusivity triggered by first shipment. Under an agreement announced last June, Impax will manufacture, supply Schering with Claritin-D 12-Hour for OTC sale; product will reach shelves in early 2003, Schering says (1"The Tan Sheet" July 1, 2002, p. 4). Impax also has licensing, supply agreement with Alavert marketer Wyeth...
You may also be interested in...
Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement
Impax Labs' agreement to supply Schering-Plough with Claritin-D 12-Hour for OTC sale is not expected to attract Federal Trade Commission scrutiny due to its nonexclusivity provisions and lack of impact on pending patent litigation, the generics firm said
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.